

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-26. (Cancelled)

Claim 27. (Currently Amended): A physicochemically stable aqueous composition for oral administration comprising:

clozapine in suspension[([,]);

a wetting agent selected from any one or more of propylene glycol, glycerin, or polyethylene glycol;

any one or more of xanthan gum, guar gum, tragacanth gum, hydroxypropyl methylcellulose, or microcrystalline cellulose; and

a buffer, wherein the pH of the composition is maintained within the range of about 6 to about 11.

Claim 28. (Cancelled)

Claim 29. (Cancelled)

Claim 30. (Previously Presented): The composition according to claim 27 wherein the buffer is a sodium phosphate/sodium hydroxide buffer.

Claim 31. (Previously Presented): The composition according to claim 27 wherein the pH is maintained in the range of from about 6 to about 8.

Claim 32. (Previously Presented): The composition according to claim 27 wherein the amount of clozapine in the composition is from about 0.1% to about 10% by weight based on the total volume of the composition.

Claim 33. (Cancelled)

Claim 34. (Previously Presented): The composition according to claim 27 comprising a wetting agent in an amount of between about 0.1% and about 15%.

Claim 35. (Cancelled)

Claim 36. (Previously Presented): The composition according to claim 27 wherein the composition includes a suspending agent and/or a preservative.

Claim 37. (Previously Presented): The composition according to claim 27 comprising a preservative selected from any one or more of methyl, propyl and butyl parabens.

Claim 38. (Currently Amended): The composition according to claim 27 wherein the composition includes: clozapine, glycerine, sodium dihydrogen phosphate dihydrate/NaOH buffer, xanthan gum, methyl paraben, propyl paraben, ~~butyl paraben~~, and water.

Claim 39. (Currently Amended): A method for preparing a physicochemically stable aqueous composition including clozapine in suspension according to claim 27, the method comprising the step of controlling the pH of the formulation between about 6 and about 11.

Claim 40. (Withdrawn): The method according to claim 39 wherein the pH is controlled between 6 and 8.

Claim 41. (Withdrawn): The method according to claim 39 wherein the method further includes the addition of PVP.

Claim 42. (Currently Amended): A method of producing a physicochemically stable aqueous composition comprising clozapine in suspension according to claim 27 comprising the following steps:

- (a) stirring the clozapine with about three quarters of ~~the~~ propylene glycol ascribed to the batch;
- (b) addition of the buffer salt (and optionally sweetening agents) dissolved in about half the volume of water ascribed to the batch with constant stirring;
- (c) adjusting the pH value with the base component of the buffer with mixing;
- (d) addition of the preservatives dissolved in the remaining propylene glycol;
- (e) slow addition of the suspending agent with continuous stirring until the mixture thickens; and,
- (f) further diluting the suspension with water to the desired end-volume.

Claim 43. (Currently Amended): A method for producing a physicochemically stable aqueous composition comprising clozapine in suspension according to claim 27 comprising the following steps:

- (a) stirring the clozapine with about three quarters of ~~the~~ glycerine ascribed to the batch;
- (b) addition of the buffer salt (and optionally sweetening agents) dissolved in about half the volume of water ascribed to the batch with constant stirring;
- (c) adjusting the pH value with the base component of the buffer with mixing;
- (d) addition of the preservatives dissolved in a small volume of water;
- (e) slow addition of the suspending agent wetted with the remaining glycerine with continuous stirring until the mixture thickens; and,
- (f) further diluting the suspension with water to the desired end-volume.

Claim 44. (Withdrawn): The method according to claim 42 wherein PVP is added as an aqueous solution following addition of the suspending agent.

Claim 45. (Withdrawn): The method according to claim 43 wherein PVP is added as an aqueous solution following addition of the suspending agent.

Claim 46. (Previously Presented): The composition according to claim 27 wherein the composition further includes a sweetening agent and/or a flavoring substance.

Claim 47. (Cancelled)

Claim 48. (Cancelled)

Claim 49. (Cancelled)

Claim 50. (Cancelled)

Claim 51. (Cancelled)

Claim 52. (Cancelled)

Claim 53. (Previously Presented): The composition according to claim 27 wherein the composition comprises: clozapine, glycerin, sodium dihydrogen phosphate dihydrate/NaOH buffer, xanthan gum, sodium methyl paraben, sodium propyl paraben and water.

Claim 54. (Cancelled)

Claim 55. (Previously Presented): The composition according to claim 27 wherein the composition is stable for at least 14 months.

Claim 56. (Cancelled)

Claim 57. (New): A physicochemically stable aqueous composition for oral administration comprising:

clozapine in suspension;

a wetting agent selected from any one or more of propylene glycol, glycerin, or

polyethylene glycol;

PVP; and

a buffer, wherein the pH of the composition is maintained within the range of about 6 to about 11.

Claim 58. (New): A physicochemically stable aqueous composition for oral administration comprising clozapine in suspension, a wetting agent, a stabilizing agent, and a buffer, wherein the pH of the composition is maintained within the range of about 6 to about 11.

Claim 59. (New): The composition according to claim 58, wherein the wetting agent is any one or more of propylene glycol, glycerin, or polyethylene glycol.

Claim 60. (New): The composition according to claim 58, wherein the stabilizing agent is any one or more of xanthan gum, guar gum, tragacanth gum, hydroxypropyl methylcellulose, or microcrystalline cellulose.